Wells Fargo lowered the firm’s price target on Inspire Medical (INSP) to $174 from $195 and keeps an Equal Weight rating on the shares. The firm notes the Q1 beat was solid, and 2025 EPS guide raise was encouraging. However, transitory headwinds due to Inspire V launch in Q2 means sales will be more second half of the year weighted, Wells adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems: Hold Rating Amid Transition Challenges and Revised Price Target
- Inspire Medical Systems: Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Inspire Medical Systems Reports Strong Q1 2025 Growth
- Inspire Medical reports Q1 EPS 10c, consensus (23c)
- Inspire Medical raises FY25 EPS view to $2.20-$2.30 from $2.10-$2.20